Kirby McInerney LLP is investigating potential claims against the Board of Directors of Bio-Reference Laboratories, Inc. (“BRLI” or the “Company”) (NASDAQ:BRLI) concerning the proposed acquisition of the Company by OPKO Health, Inc. (“OPKO”). Pursuant to the terms of the definitive merger agreement, BRLI stockholders will receive 2.75 shares of OPKO common stock for each share of BRLI common stock they own, a value of $52.58 per share of BRLI common stock.

The investigation concerns whether the BRLI Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the proposed consideration adequately values the Company’s common stock.

If you are a BRLI stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at bwalker@kmllp.com, or telephone at (212) 699-1145 or toll free at (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150604006434/en/